Publisher
Springer Berlin Heidelberg
Reference32 articles.
1. Baglin T, Gray E, Greaves M, Hunt BJ, Keeling D, Machin S, Mackie I, Makris M, Nokes T, Perry D, Tait RC, Walker I, Watson H Clinical guidelines for testing for heritable thrombophilia (2010) Br J Haematol, in press
2. Baudo F, DeGasperi A, deCataldo F, Caimi TM, Cattaneo D, Redaelli R, Pannacciulli E, Corti A, Mazza E, Belli L (1992) Antithrombin III supplementation during orthotopic liver transplantation in cirrhotic patients: a randomized trial. Thromb Res 68:409–416
3. Bauersachs RM, Dudenhausen J, Faridi A, Fischer T, Fung S, Geisen U, Harenberg J, Herchenhan E, Keller F, Kemkes-Matthes B, Schinzel H, Spannagl M, Thaler CJ; EThIG Investigators (2007) Risk stratification and heparin prophylaxis to prevent venous thromboembolism in pregnant women Thromb Haemost 98:1237–1245
4. Bergmann F, Hoyer PF, Vigano D’Angelo S, Mazzola G, Oestereich C, Barthels M, D’Angelo A (1995) Severe autoimmune protein S deficiency in boy with idiopathic purpura fulminans. Br J Haemat 89:610–614
5. Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, Lopez-Rodriguez A, Steingrub JS, Garber GE, Helterbrand JD, Ely EW, Fisher CJ Jr (2001) For the Recombinant Human Activated Protein C Worldwide Evaluation in Severe Sepsis (PROWESS) Study Group. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 344:699–709